Adam Bress

Adam Bress, PharmD, MS

Languages spoken: English

Academic Information

Departments Primary - Population Health Sciences

Lab

Research Interests

  • Optimizing Medication Use for Cardiovascular and Neurodegenerative Disease Prevention
  • Pharmacoepidemiology and Pharmacoeconomics of Cardiovascular Disease Medications
  • Evaluating the Use, Misuse, Underuse, Effectiveness, and Safety of Cardiovascular Disease Medications
  • Applying Causal Inference Methods to Assess the Effects and Safety of Cardiovascular Disease Medications
  • Mentored Research for Junior Faculty
  • Cardiovascular Disease Prevention and Treatment

Visit Dr. Bress' Lab Site

Dr. Bress is currently an Associate Professor of Population Health Sciences with Tenure in the Division of Health System Innovation and Research and an Investigator at the VA Salt Lake City Health Care System. He also serves as the Vice Chair of Reserach for the Department of Population Health Sciences.

Dr. Bress is a formally-trained cardiovascular clinical pharmacist and population scientist. His research is focused on the prevention and treatment of cardiovascular disease, optimizing medication use, and reducing health disparities. He is particularly interested in studying antihypertensive medication use, responses, and outcomes to help patients and providers, as well as health systems, payers, governments, and population health managers, make better decisions about how to treat and control high blood pressure. Dr. Bress's research has been published in the New England Journal of Medicine, The Journal of the American College of Cardiology, and Circulation. He was elected as the 2020 National Academy of Medicine Fellow in Pharmacy.

Dr. Bress is a former NHLBI K01 awardee (K01HL133468) and is currently NIH-funded as a Principal Investigator by an NHLBI R01 (R01HL139837) and two NIA R01s (R01AG06580501 and R01AG074989). He also received grant support from the biomedical industry as PI for investigator-initiated research projects focused on cardiovascular pharmacoepidemiology.

Dr. Bress has established collaborations with a multi-disciplinary team of investigators in hypertension, cardiology, health services research, epidemiology, and pharmacogenetics at the University of Utah and around the country. He is an active member of the hypertension working groups for two ongoing NIH-funded cohort studies including the Jackson Heart Study (JHS), the Coronary Artery Risk Development in Young Adults (CARDIA) Study, and the Women's Health Initiative (WHI). He is also an active member of the Systolic Blood Pressure Intervention Trial (SPRINT) Research Group.

Dr. Bress received his Doctor of Pharmacy degree from the University of Maryland, and his Masters of Science in Clinical and Translational Science from the University of Illinois at Chicago School of Public Health with a focus on epidemiology. He completed his residency in pharmacy practice at Yale-New Haven Hospital and Cardiology at the University of Illinois at Chicago. He subsequently completed his post-doctoral research fellowship in cardiovascular pharmacogenomics at the University of Illinois at Chicago.

Research Statement

I am a cardiovascular clinical pharmacist with training in epidemiology and pharmacogenetics. We focus on disparities in prevention and treatment of cardiovascular disease with a focus on hypertension and antihypertensive medication use. Using pharmacoepidemiology and pharmacogenetics, we try to better understand causes of racial differences in medication responses and outcomes. We apply these findings to understand the population-level impact, generalizability, and cost-effectiveness in diverse groups.

Education History

Graduate Training University of Illinois at Chicago School of Public Health
 MS
University of Illinois at Chicago
 Research Fellow
Residency University of Illinois at Chicago
 Resident
Yale-New Haven Hospital
 Resident
Doctoral Training University of Maryland
 PharmD

Selected Publications

Journal Article

  1. Jacobs JA, Rodgers A, Bellows BK, Hernandez I, Wang N, Derington CG, King JB, Zheutlin AR, Whelton PK, Egan BM, Cushman WC, Bress AP (2024). Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021. Hypertension, 81(11), 2307-2317. (Read full article)
  2. Xu Y, Derington CG, Addo DK, He T, Jacobs JA, Mohanty AF, An J, Cushman WC, Ho PM, Bellows BK, Cohen JB, Bress AP (2024). Trends in Initial Antihypertensive Medication Prescribing Among >2.8 Million Veterans Newly Diagnosed With Hypertension, 2000 to 2019. J Am Heart Assoc, 13(20), e036557. (Read full article)
  3. Rosner B, Cook NR, Glynn RJ, Bress A, Derington AG, Falkner B, Allen N (2024). Use of Censored Data Methods to Estimate Blood Pressure Percentiles in US Adults. Am J Epidemiol. (Read full article)
  4. Jacobs JA, Carter SJ, Bullock G, Carey JR, Pan IZ, Kinsey MS, Zheutlin AR, Kapelios CJ, Raju S, Fang JC, Shah KS, Bress AP (2024). Optimal Initial Intravenous Loop Diuretic Dosing in Acute Decompensated Heart Failure. JACC Adv, 3(10), 101250. (Read full article)
  5. Gobourne A, Ringel JB, King A, Safford M, Riffin C, Adelman R, Bress A, Paul TK, Durant RW, Roth DL, Sterling MR (2024). Association Between Caregiver Strain and Self-Care Among Caregivers With Hypertension: Findings From the REGARDS Study. J Am Heart Assoc, 13(15), e033477. (Read full article)
  6. Pajewski NM, Beddhu S, Bress AP, Chang TI, Chertow GM, Cheung AK, Cushman WC, Freedman BI, Greene T, Johnson KC, Jaeger BC, Tamura MK, Lewis CE, Rahman M, Reboussin DM, Rocco MV, Williamson JD, Whelton PK, Wright JT Jr, Drawz PE, Ix JH (2024). The Legacy Effect of Intensive versus Standard BP Control on the Incidence of Needing Dialysis or Kidney Transplantation. J Am Soc Nephrol. (Read full article)
  7. Sharareh N, Zheutlin AR, Qato DM, Guadamuz J, Bress A, Vos RO (2024). Access to community pharmacies based on drive time and by rurality across the contiguous United States. J Am Pharm Assoc (Wash), 64(2), 476-482. (Read full article)
  8. Zheutlin AR, Sharareh N, Guadamuz JS, Berchie RO, Derington CG, Jacobs JA, Mondesir FL, Alexander GC, Levitan EB, Safford M, Vos RO, Qato DM, Bress AP (2024). Association Between Pharmacy Proximity With Cardiovascular Medication Use and Risk Factor Control in the United States. J Am Heart Assoc, e031717. (Read full article)
  9. Tajeu GS, Ruiz-Negrn N, Moran AE, Zhang Z, Kolm P, Weintraub WS, Bress AP, Bellows BK (2024). Cost of Cardiovascular Disease Event and Cardiovascular Disease Treatment-Related Complication Hospitalizations in the United States. Circ Cardiovasc Qual Outcomes, e009999. (Read full article)
  10. Jacobs JA, Derington CG, Zheutlin AR, King JB, Cohen JB, Bucheit J, Kronish IM, Addo DK, Morisky DE, Greene TH, Bress AP (2024). Association Between Self-Reported Medication Adherence and Therapeutic Inertia in Hypertension: A Secondary Analysis of SPRINT (Systolic Blood Pressure Intervention Trial). J Am Heart Assoc, 13(3), e031574. (Read full article)
  11. Zhang F, Bryant KB, Moran AE, Zhang Y, Cohen JB, Bress AP, Sheppard JP, King JB, Derington CG, Weintraub WS, Kronish IM, Shea S, Bellows BK (2024). Effectiveness of Hypertension Management Strategies in SPRINT-Eligible US Adults: A Simulation Study. J Am Heart Assoc, 13(2), e032370. (Read full article)
  12. Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P (2023). Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States. J Am Heart Assoc, 13(1), e032413. (Read full article)
  13. Jacobs JA, Zheutlin AR, Derington CG, King JB, Pandey A, Bress AP (2023). Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020. Am J Prev Cardiol, 17, 100624. (Read full article)
  14. Mentias A, Keshvani N, Sumarsono A, Desai R, Khan MS, Menon V, Hsich E, Bress AP, Jacobs J, Vasan RS, Fonarow GC, Pandey A (2023). Patterns, Prognostic Implications, and Rural-Urban Disparities in Optimal GDMT Following HFrEF Diagnosis Among Medicare Beneficiaries. JACC Heart Fail. (Read full article)
  15. Baron KG, Duffecy J, Simonsen S, Bress A, Conroy MB, Greene T, Allen C, Vallejo S (2023). Sleep Technology Intervention to Target Cardiometabolic Health (STITCH): a randomized controlled study of a behavioral sleep extension intervention compared to an education control to improve sleep duration, blood pressure, and cardiometabolic health among adults with elevated blood pressure/hypertension. Trials, 24(1), 658. (Read full article)
  16. King JB, Berchie RO, Derington CG, Marcum ZA, Scharfstein DO, Greene TH, Herrick JS, Jacobs JA, Zheutlin AR, Bress AP, Cohen JB (2023). New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINT. J Am Heart Assoc, 12(17), e030311. (Read full article)
  17. Zheutlin AR, Jacobs JA, Derington CG, Chaitoff A, Navar AM, Bress AP (2023). Age-based disparities in statin use for primary prevention in US adults: National Health and Nutrition Examination Surveys 2013-2020. J Clin Lipidol. (Read full article)
  18. King JB, Derington CG, Herrick JS, Jacobs JA, Zheutlin AR, Conroy MB, Cushman WC, Bress AP (2023). Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial. Hypertension, 80(8), 1749-1758. (Read full article)
  19. Derington CG, Bress AP, Berchie RO, Herrick JS, Shen J, Ying J, Greene T, Tajeu GS, Sakhuja S, Ruiz-Negrn N, Zhang Y, Howard G, Levitan EB, Muntner P, Safford MM, Whelton PK, Weintraub WS, Moran AE, Bellows BK, SPRINT Research Group (2023). Estimated population health benefits of intensive systolic blood pressure treatment among SPRINT-eligible US adults. Am J Hypertens, 36(9), 498-508. (Read full article)
  20. Jaeger BC, Chen L, Foti K, Hardy ST, Bress AP, Kane SP, Huang L, Herrick JS, Derington CG, Poudel B, Christenson A, Colantonio LD, Muntner P (2023). Hypertension Statistics for US Adults: An Open-Source Web Application for Analysis and Visualization of National Health and Nutrition Examination Survey Data. Hypertension, 80(6), 1311-1320. (Read full article)
  21. Zheutlin AR, Addo DK, Jacobs JA, Derington CG, Herrick JS, Greene TH, Stulberg EL, Berlowitz DR, Williamson JD, Pajewski NM, Supiano MA, Bress AP (2023). Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT. Hypertension, 80(7), 1484-1493. (Read full article)
  22. Derington CG, Bress AP, Herrick JS, Jacobs JA, Zheutlin AR, Berchie RO, Conroy MB, Cushman WC, King JB (2023). Antihypertensive Medication Regimens Used by US Adults With Hypertension and the Potential for Fixed-Dose Combination Products: The National Health and Nutrition Examination Surveys 2015 to 2020. J Am Heart Assoc, 12(11), e028573. (Read full article)
  23. Ghazi L, Shen J, Ying J, Derington CG, Cohen JB, Marcum ZA, Herrick JS, King JB, Cheung AK, Williamson JD, Pajewski NM, Bryan N, Supiano M, Sonnen J, Weintraub WS, Greene TH, Bress AP (2023). Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical Trial. JAMA Netw Open, 6(5), e2314443. (Read full article)
  24. Muntner P, Foti K, Wang Z, Alanaeme CJ, Choi E, Bress AP, Shimbo D, Kronish I (2023). Discontinuation of renin-angiotensin system inhibitors during the early stage of the COVID-19 pandemic. Am J Hypertens. (Read full article)
  25. Jacobs JA, Addo DK, Zheutlin AR, Derington CG, Essien UR, Navar AM, Hernandez I, Lloyd-Jones DM, King JB, Rao S, Herrick JS, Bress AP, Pandey A (2023). Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020. JAMA Cardiol, 8(5), 443-452. (Read full article)
  26. Tang H, Shao H, Shaaban CE, Yang K, Brown J, Anton S, Wu Y, Bress A, Donahoo WT, DeKosky ST, Bian J, Guo J (2023). Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies. J Am Geriatr Soc. (Read full article)
  27. Marcum ZA, Gabriel N, Bress AP, Hernandez I (2023). Association of New Use of Antihypertensives That Stimulate vs Inhibit Type 2 and 4 Angiotensin II Receptors With Dementia Among Medicare Beneficiaries. JAMA Netw Open, 6(1), e2249370. (Read full article)
  28. Derington CG, Bress AP, Moran AE, Weintraub WS, Herrick JS, Cushman WC, Kronish IM, Stults B, Shimbo D, Muntner P, Greene T, Bates JT, Chang TI, Katz LA, Rehman SU, Roumie CL, Tamariz L, King JB (2022). Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial. Hypertension, 80(3), 590-597. (Read full article)
  29. Xu Y, Greene TH, Bress AP, Bellows BK, Zhang Y, Zhang Z, Kolm P, Weintraub WS, Moran AS, Shen J (2022). An efficient approach for optimizing the cost-effective individualized treatment rule using conditional random forest. Stat Methods Med Res, 31(11), 2122-2136. (Read full article)
  30. Buckley LF, Baker WL, Van Tassell BW, Cohen JB, Alkhezi O, Bress AP, Dixon DL (2022). Systolic Blood Pressure Time in Target Range and Major Adverse Kidney and Cardiovascular Events. Hypertension, 80, 305-313. (Read full article)
  31. Zheutlin AR, Derington CG, Herrick JS, Rosenson RS, Poudel B, Safford MM, Brown TM, Jackson EA, Woodward M, Reading S, Orroth K, Exter J, Virani SS, Muntner P, Bress AP (2022). Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019. Circ Cardiovasc Qual Outcomes, 15(12), e008861. (Read full article)
  32. Jaeger BC, Bress AP, Bundy JD, Cheung AK, Cushman WC, Drawz PE, Johnson KC, Lewis CE, Oparil S, Rocco MV, Rapp SR, Supiano MA, Whelton PK, Williamson JD, Wright JT Jr, Reboussin DM, Pajewski NM (2022). Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol, 7, 1138-1146. (Read full article)
  33. Hsiao CJ, Dumeny L, Bress AP, Johnson DA, Shimbo D, Cavallari LH, Mulligan CJ (2022). Identification of a SGCD x Discrimination interaction effect on systolic blood pressure in African American adults in the Jackson Heart Study. Am J Hypertens, 35, 938-947. (Read full article)
  34. Kim DH, Tatsuoka C, Chen Z, Wright JT Jr, Odden MC, Beddhu S, Bellows BK, Bress A, Carson T, Cushman WC, Johnson KC, Morisky DE, Punzi H, Tamariz L, Yang S, Wei LJ (2022). Intensive Versus Standard Blood Pressure Lowering and Days Free of Cardiovascular Events and Serious Adverse Events: a Post Hoc Analysis of Systolic Blood Pressure Intervention Trial. J Gen Intern Med, 37, 3797-3804. (Read full article)
  35. Tajeu GS, Colvin CL, Hardy ST, Bress AP, Gaye B, Jaeger BC, Ogedegbe G, Sakhuja S, Sims M, Shimbo D, OBrien EC, Spruill TM, Muntner P (2022). Prevalence, risk factors, and cardiovascular disease outcomes associated with persistent blood pressure control: The Jackson Heart Study. PLoS One, 17(8), e0270675. (Read full article)
  36. Green MB, Shimbo D, Schwartz JE, Bress AP, King JB, Muntner P, Sheppard JP, McManus RJ, Kohli-Lynch CN, Zhang Y, Shea S, Moran AE, Bellows BK (2022). Cost-effectiveness of masked hypertension screening and treatment in US adults with suspected masked hypertension - a simulation study. Am J Hypertens, 35, 752-762. (Read full article)
  37. Kelly TN, Sun X, He KY, Brown MR, Taliun SAG, Hellwege JN, Irvin MR, Mi X, Brody JA, Franceschini N, Guo X, Hwang SJ, de Vries PS, Gao Y, Moscati A, Nadkarni GN, Yanek LR, Elfassy T, Smith JA, Chung RH, Beitelshees AL, Patki A, Aslibekyan S, Blobner BM, Peralta JM, Assimes TL, Palmas WR, Liu C, Bress AP, Huang Z, Becker LC, Hwa CM, OConnell JR, Carlson JC, Warren HR, Das S, Giri A, Martin LW, Craig Johnson W, Fox ER, Bottinger EP, Razavi AC, Vaidya D, Chuang LM, Chang YC, Naseri T, Jain D, Kang HM, Hung AM, Srinivasasainagendra V, Snively BM, Gu D, Montasser ME, Reupena MS, Heavner BD, LeFaive J, Hixson JE, Rice KM, Wang FF, Nielsen JB, Huang J, Khan AT, Zhou W, Nierenberg JL, Laurie CC, Armstrong ND, Shi M, Pan Y, Stilp AM, Emery L, Wong Q, Hawley NL, Minster RL, Curran JE, Munroe PB, Weeks DE, North KE, Tracy RP, Kenny EE, Shimbo D, Chakravarti A, Rich SS, Reiner AP, Blangero J, Redline S, Mitchell BD, Rao DC, Ida Chen YD, Kardia SLR, Kaplan RC, Mathias RA, He J, Psaty BM, Fornage M, Loos RJF, Correa A, Boerwinkle E, Rotter JI, Kooperberg C, Edwards TL, Abecasis GR, Zhu X, Levy D, Arnett DK, Morrison AC, NHLBI Trans-Omics for Precision Medicine TOPMed Consortium The Samoan Obesity Lifestyle and Genetic Adaptations Study OLaGA Group (2022). Insights From a Large-Scale Whole-Genome Sequencing Study of Systolic Blood Pressure, Diastolic Blood Pressure, and Hypertension. Hypertension, 79, 101161HYPERTENSIONAHA12219324. (Read full article)
  38. Derington CG, Bress AP, Herrick JS, Fan W, Wong ND, Andrade KE, Johnson J, Philip S, Abrahamson D, Jiao L, Bhatt DL, Weintraub WS (2022). The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl. Am J Prev Cardiol, 10, 100345. (Read full article)
  39. Yang WY, Izzi B, Bress AP, Thijs L, Citterio L, Wei FF, Salvi E, Delli Carpini S, Manunta P, Cusi D, Hoylaerts MF, Luttun A, Verhamme P, Hardikar S, Nawrot TS, Staessen JA, Zhang ZY (2022). Association of colorectal cancer with genetic and epigenetic variation in PEAR1-A population-based cohort study. PLoS One, 17(4), e0266481. (Read full article)
  40. Jacobs JA, Shah RU, Bress AP (2022). Asymptomatic hypertension in the hospital setting: primum non nocere. J Hum Hypertens, 36, 781-784. (Read full article)
  41. He KY, Kelly TN, Wang H, Liang J, Zhu L, Cade BE, Assimes TL, Becker LC, Beitelshees AL, Bielak LF, Bress AP, Brody JA, Chang YC, Chang YC, de Vries PS, Duggirala R, Fox ER, Franceschini N, Furniss AL, Gao Y, Guo X, Haessler J, Hung YJ, Hwang SJ, Irvin MR, Kalyani RR, Liu CT, Liu C, Martin LW, Montasser ME, Muntner PM, Mwasongwe S, Naseri T, Palmas W, Reupena MS, Rice KM, Sheu WH, Shimbo D, Smith JA, Snively BM, Yanek LR, Zhao W, Blangero J, Boerwinkle E, Chen YI, Correa A, Cupples LA, Curran JE, Fornage M, He J, Hou L, Kaplan RC, Kardia SLR, Kenny EE, Kooperberg C, Lloyd-Jones D, Loos RJF, Mathias RA, McGarvey ST, Mitchell BD, North KE, Peyser PA, Psaty BM, Raffield LM, Rao DC, Redline S, Reiner AP, Rich SS, Rotter JI, Taylor KD, Tracy R, Vasan RS, Samoan Obesity Lifestyle and Genetic Adaptations Study OLaGA Group NHLBI Trans-Omics for Precision Medicine TOPMed Consortium, Morrison AC, Levy D, Chakravarti A, Arnett DK, Zhu X (2022). Rare coding variants in RCN3 are associated with blood pressure. BMC Genomics, 23(1), 148. (Read full article)
  42. Sakhuja S, Jaeger BC, Akinyelure OP, Bress AP, Shimbo D, Schwartz JE, Hardy ST, Howard G, Drawz P, Muntner P (2022). Potential impact of systematic and random errors in blood pressure measurement on the prevalence of high office blood pressure in the United States. J Clin Hypertens (Greenwich), 24, 263-270. (Read full article)
  43. Parcha V, Heindl B, Kalra R, Bress A, Rao S, Pandey A, Gower B, Irvin MR, McDonald MN, Li P, Arora G, Arora P (2022). Genetic European Ancestry and Incident Diabetes in Black Individuals: Insights From the SPRINT Trial. Circ Genom Precis Med, 15(1), e003468. (Read full article)
  44. Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Kolm P (2022). Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open, 5(2), e2148172. (Read full article)
  45. Bellows BK, Xu J, Sheppard JP, Schwartz JE, Shimbo D, Muntner P, McManus RJ, Moran AE, Bryant KB, Cohen LP, Bress AP, King JB, Shikany JM, Green BB, Yano Y, Clark Iii D, Zhang Y (2022). Predicting Out-of-Office Blood Pressure in a diverse US population. Am J Hypertens, 35, 533-542. (Read full article)
  46. Marcum ZA, Cohen JB, Zhang C, Derington CG, Greene TH, Ghazi L, Herrick JS, King JB, Cheung AK, Bryan N, Supiano MA, Sonnen JA, Weintraub WS, Williamson J, Pajewski NM, Bress AP, Systolic Blood Pressure Intervention Trial SPRINT Research Group (2022). Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment. JAMA Netw Open, 5(1), e2145319. (Read full article)
  47. King JB, Pinheiro LC, Bryan Ringel J, Bress AP, Shimbo D, Muntner P, Reynolds K, Cushman M, Howard G, Manly JJ, Safford MM (2021). Multiple Social Vulnerabilities to Health Disparities and Hypertension and Death in the REGARDS Study. Hypertension, 79(1), 196-206. (Read full article)
  48. Smith SM, Desai RA, Walsh MG, Nilles EK, Shaw K, Smith M, Chamberlain AM, Derington CG, Bress AP, Chuang CH, Ford DE, Taylor BW, Chandaka S, Patel LP, McClay J, Priest E, Fuloria J, Doshi K, Ahmad FS, Viera AJ, Faulkner M, OBrien EC, Pletcher MJ, Cooper-DeHoff RM (2022). Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab. Am Heart J Plus, 13, 100112. (Read full article)
  49. Langford AT, Butler M, Booth JN, Jin P, Bress AP, Tanner RM, Kalinowski J, Blanc J, Seixas A, Shimbo D, Sims M, Ogedegbe G, Spruill TM (2021). Stress and Depression Are Associated With Life's Simple 7 Among African Americans With Hypertension: Findings From the Jackson Heart Study. Am J Hypertens, 34(12), 1311-1321. (Read full article)
  50. Mohanty AF, Levitan EB, King JB, Dodson JA, Vardeny O, Cook J, Herrick JS, He T, Patterson OV, Alba PR, Russo PA, Obi EN, Choi ME, Fang JC, Bress AP (2021). Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. J Am Heart Assoc, 10(20), e020474. (Read full article)
  51. Zheutlin AR, Derington CG, King JB, Berchie RO, Herrick JS, Dixon DL, Cohen JB, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress AP (2021). Factors associated with antihypertensive monotherapy among US adults with treated hypertension and uncontrolled blood pressure overall and by race/ethnicity, National Health and Nutrition Examination Survey 2013-2018. Am Heart J, 248, 150-159. (Read full article)
  52. Colvin CL, Poudel B, Bress AP, Derington CG, King JB, Wen Y, Chen L, Bittner V, Brown TM, Monda KL, Mues KE, Rosenson RS, Jackson EA, Muntner P, Colantonio LD (2021). Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction. J Clin Lipidol, 15(5), 665-673. (Read full article)
  53. Rethy LB, Feinstein MJ, Achenbach CJ, Townsend RR, Bress AP, Shah SJ, Cohen JB (2021). Antihypertensive Class and Cardiovascular Outcomes in Patients With HIV and Hypertension. Hypertension, 77(6), 2023-2033. (Read full article)
  54. Bellows BK, Zhang Y, Zhang Z, Lloyd-Jones DM, Bress AP, King JB, Kolm P, Cushman WC, Johnson KC, Tamariz L, Oelsner EC, Shea S, Newman AB, Ives DG, Couper D, Moran AE, Weintraub WS (2021). Estimating Systolic Blood Pressure Intervention Trial Participant Posttrial Survival Using Pooled Epidemiologic Cohort Data. J Am Heart Assoc, 10(10), e020361. (Read full article)
  55. Li S, Schwartz JE, Shimbo D, Muntner P, Shikany JM, Booth JN 3rd, Allen NB, Jaeger BC, Bress AP, King JB, Clark D 3rd, Butler KR, Correa A, Moran AE, Bellows BK, Zhang Y (2020). Estimated Prevalence of Masked Asleep Hypertension in US Adults. JAMA Cardiol, 6(5), 568-573. (Read full article)
  56. Bress AP, Greene T, Derington CG, Shen J, Xu Y, Zhang Y, Ying J, Bellows BK, Cushman WC, Whelton PK, Pajewski NM, Reboussin D, Beddu S, Hess R, Herrick JS, Zhang Z, Kolm P, Yeh RW, Basu S, Weintraub WS, Moran AE, SPRINT Research Group (2021). Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. J Am Coll Cardiol, 77(16), 1977-1990. (Read full article)
  57. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP (2021). Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS One, 16(4), e0248080. (Read full article)
  58. Derington CG, Colantonio LD, Herrick JS, Cook J, King JB, Rosenson RS, Poudel B, Monda KL, Navar AM, Mues KE, Stevens VW, Nelson RE, Vanneman ME, Muntner P, Bress AP (2021). Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. J Am Heart Assoc, 10(8), e019254. (Read full article)
  59. Xu Y, Greene TH, Bress AP, Sauer BC, Bellows BK, Zhang Y, Weintraub WS, Moran AE, Shen J (2020). Estimating the optimal individualized treatment rule from a cost-effectiveness perspective. Biometrics, 78(1), 337-351. (Read full article)
  60. Rao S, Segar MW, Bress AP, Arora P, Vongpatanasin W, Agusala V, Essien UR, Correa A, Morris AA, de Lemos JA, Pandey A (2020). Association of Genetic West African Ancestry, Blood Pressure Response to Therapy, and Cardiovascular Risk Among Self-Reported Black Individuals in the Systolic Blood Pressure Reduction Intervention Trial (SPRINT). JAMA Cardiol. (Read full article)
  61. Colvin CL, King JB, Oparil S, Wright JT Jr, Ogedegbe G, Mohanty A, Hardy ST, Huang L, Hess R, Muntner P, Bress A (2020). Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report. JAMA Netw Open, 3(11), e2025127. (Read full article)
  62. Langford AT, Akinyelure OP, Moore TL Jr, Howard G, Min YI, Hillegass WB, Bress AP, Tajeu GS, Butler M, Jaeger BC, Yano Y, Shimbo D, Ogedegbe G, Calhoun D, Booth JN 3rd, Muntner P (2020). Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study. Hypertension, 76(5), 1600-1607. (Read full article)
  63. Rapp SR, Gaussoin SA, Sachs BC, Chelune G, Supiano MA, Lerner AJ, Wadley VG, Wilson VM, Fine LJ, Whittle JC, Auchus AP, Beddhu S, Berlowitz DR, Bress AP, Johnson KC, Krousel-Wood M, Martindale-Adams J, Miller EC, Rifkin DE, Snyder JK, Tamariz L, Wolfgram DF, Cleveland ML, Yang M, Nichols LO, Bryan RN, Reboussin DM, Williamson JD, Pajewski NM, SPRINT Research Group (2020). Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial. Lancet Neurol, 19(11), 899-907. (Read full article)
  64. An J, Derington CG, Luong T, Olson KL, King JB, Bress AP, Jackevicius CA (2020). Fixed-Dose Combination Medications for Treating Hypertension: A Review of Effectiveness, Safety, and Challenges. Curr Hypertens Rep, 22(11), 95. (Read full article)
  65. Derington CG, Cohen JB, Bress AP (2020). Restoring the upward trend in blood pressure control rates in the United States: a focus on fixed-dose combinations. J Hum Hypertens, 34(9), 617-623. (Read full article)
  66. Cohen JB, Hanff TC, Bress AP, South AM (2020). Relationship Between ACE2 and Other Components of the Renin-Angiotensin System. Curr Hypertens Rep, 22(7), 44. (Read full article)
  67. Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress AP (2020). Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016. Hypertension, 75(4), 973-981. (Read full article)
  68. Pajewski NM, Berlowitz DR, Bress AP, Callahan KE, Cheung AK, Fine LJ, Gaussoin SA, Johnson KC, King J, Kitzman DW, Kostis JB, Lerner AJ, Lewis CE, Oparil S, Rahman M, Reboussin DM, Rocco MV, Snyder JK, Still C, Supiano MA, Wadley VG, Whelton PK, Wright JT Jr, Williamson JD (2019). Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial. J Am Geriatr Soc, 68(3), 496-504. (Read full article)
  69. Van Tassell JC, Shimbo D, Hess R, Kittles R, Wilson JG, Jorde LB, Li M, Lange LA, Lange EM, Muntner P, Bress AP (2020). Association of West African ancestry and blood pressure control among African Americans taking antihypertensive medication in the Jackson Heart Study. J Clin Hypertens (Greenwich), 22(2), 157-166. (Read full article)
  70. Rathi N, Whelton PK, Chertow GM, Cushman WC, Cheung AK, Wei G, Boucher R, Kimmel PL, Bress AP, Kramer HJ, Al-Marji C, Greene T, Beddhu S (2019). Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events. Am J Hypertens, 32(12), 1170-1177. (Read full article)
  71. Derington CG, King JB, Bryant KB, McGee BT, Moran AE, Weintraub WS, Bellows BK, Bress AP (2019). Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care. Curr Hypertens Rep, 21(12), 91. (Read full article)
  72. Mohanty AF, Levitan EB, Dodson JA, Vardeny O, King JB, LaFleur J, He T, Patterson OV, Alba PR, Russo PA, Choi ME, Bress AP (2019). Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan. Circ Heart Fail, 12(11), e005691. (Read full article)
  73. Anstey DE, Tanner RM, Booth JN 3rd, Bress AP, Diaz KM, Sims M, Ogedegbe G, Muntner P, Abdalla M (2019). Inappropriate Left Ventricular Mass and Cardiovascular Disease Events and Mortality in Blacks: The Jackson Heart Study. J Am Heart Assoc, 8(16), e011897. (Read full article)
  74. Owlia M, Dodson JA, King JB, Derington CG, Herrick JS, Sedlis SP, Crook J, DuVall SL, LaFleur J, Nelson R, Patterson OV, Shah RU, Bress AP (2019). Angina Severity, Mortality, and Healthcare Utilization Among Veterans With Stable Angina. J Am Heart Assoc, 8(15), e012811. (Read full article)
  75. Tajeu GS, Kent ST, Huang L, Bress AP, Cuffee Y, Halpern MT, Kronish IM, Krousel-Wood M, Mefford MT, Shimbo D, Muntner P (2019). Antihypertensive Medication Nonpersistence and Low Adherence for Adults <65 Years Initiating Treatment in 2007-2014. Hypertension, 74(1), 35-46. (Read full article)
  76. Derington CG, Gums TH, Bress AP, Herrick JS, Greene TH, Moran AE, Weintraub WS, Kronish IM, Morisky DE, Trinkley KE, Saseen JJ, Reynolds K, Bates JT, Berlowitz DR, Chang TI, Chonchol M, Cushman WC, Foy CG, Herring CT, Katz LA, Krousel-Wood M, Pajewski NM, Tamariz L, King JB, SPRINT Research Group (2019). Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT. Hypertension, HYPERTENSIONAHA11912907. (Read full article)
  77. Tajeu GS, Kent ST, Guang L, Bress AP, Cuffee Y, Halpern MT, Kronish IM, Krousel-Wood M, Mefford MT, Shimbo D, Muntner P (04/16/2019). Trends in Antihypertensive Medication Nonpersistence and Low Adherence among US Adults <65 years of age with Commercial Health Insurance Initiating Treatment Between 2007 and 2014. Hypertension, In Press.
  78. Jaeger BC, Anstey DE, Bress AP, Booth JN 3rd, Butler M, Clark D 3rd, Howard G, Kalinowski J, Long DL, Ogedegbe G, Plante TB, Shimbo D, Sims M, Supiano MA, Whelton PK, Muntner P (2019). Cardiovascular Disease and Mortality in Adults Aged ≥60 Years According to Recommendations by the American College of Cardiology/American Heart Association and American College of Physicians/American Academy of Family Physicians. Hypertension, 73(2), 327-334. (Read full article)
  79. He KY, Li X, Kelly TN, Liang J, Cade BE, Assimes TL, Becker LC, Beitelshees AL, Bress AP, Chang YC, Chen YI, de Vries PS, Fox ER, Franceschini N, Furniss A, Gao Y, Guo X, Haessler J, Hwang SJ, Irvin MR, Kalyani RR, Liu CT, Liu C, Martin LW, Montasser ME, Muntner PM, Mwasongwe S, Palmas W, Reiner AP, Shimbo D, Smith JA, Snively BM, Yanek LR, Boerwinkle E, Correa A, Cupples LA, He J, Kardia SLR, Kooperberg C, Mathias RA, Mitchell BD, Psaty BM, Vasan RS, Rao DC, Rich SS, Rotter JI, Wilson JG, NHLBI Trans-Omics for Precision Medicine TOPMed Consortium TOPMed Blood Pressure Working Group, Chakravarti A, Morrison AC, Levy D, Arnett DK, Redline S, Zhu X (2019). Leveraging linkage evidence to identify low-frequency and rare variants on 16p13 associated with blood pressure using TOPMed whole genome sequencing data. Hum Genet, 138(2), 199-210. (Read full article)
  80. Bress AP, Colantonio LD, Cooper RS, Kramer H, Booth JN 3rd, Odden MC, Bibbins-Domingo K, Shimbo D, Whelton PK, Levitan EB, Howard G, Bellows BK, Kleindorfer D, Safford MM, Muntner P, Moran AE (2019). Potential Cardiovascular Disease Events Prevented with Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. Circulation, 139(1), 24-36. (Read full article)
  81. Case BC, Bress AP, Kolm P, Philip S, Herrick JS, Granowitz CB, Toth PP, Fan W, Wong ND, Hull M, Weintraub WS (2019). The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. J Clin Lipidol, 13(5), 754-761. (Read full article)
  82. Yano Y, Reis JP, Colangelo LA, Shimbo D, Viera AJ, Allen NB, Gidding SS, Bress AP, Greenland P, Muntner P, Lloyd-Jones DM (2018). Association of Blood Pressure Classification in Young Adults Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Cardiovascular Events Later in Life. JAMA, 320(17), 1774-1782. (Read full article)
  83. Colantonio LD, Booth JN 3rd, Bress AP, Whelton PK, Shimbo D, Levitan EB, Howard G, Safford MM, Muntner P (2018). 2017 ACC/AHA Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk. J Am Coll Cardiol, 72(11), 1187-1197. (Read full article)
  84. LaFleur J, Bress AP, Myers J, Rosenblatt L, Crook J, Knippenberg K, Bedimo R, Tebas P, Nyman H, Esker S (2018). Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals. Infect Dis Ther, 7(2), 293-308. (Read full article)
  85. Booth JN III, Li M, Shimbo D, Hess R, Irvin MR, Kittles R, Wilson JG, Jorde LB, Cheung AK, Lange LA, Lange EM, Yano Y, Muntner P, Bress AP (2018). West African Ancestry and Nocturnal Blood Pressure in African Americans: The Jackson Heart Study. Am J Hypertens, 31(6), 706-714. (Read full article)
  86. LaFleur J, Bress AP, Esker S, Knippenberg K, Crook J, Nyman H, Bedimo R, Tebas P, Rosenblatt L (2018). Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals. J Acquir Immune Defic Syndr, 77(3), 325-330. (Read full article)
  87. Still CH, Rodriguez CJ, Wright JT Jr, Craven TE, Bress AP, Chertow GM, Whelton PK, Whittle JC, Freedman BI, Johnson KC, Foy CG, He J, Kostis JB, Lash JP, Pedley CF, Pisoni R, Powell JR, Wall BM, SPRINT Writing Group (2017). Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial. Am J Hypertens, 31(1), 97-107. (Read full article)
  88. LaFleur J, Bress AP, Rosenblatt L, Crook J, Sax PE, Myers J, Ritchings C (2017). Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS, 31(15), 2095-2106. (Read full article)
  89. King JB, Azadani PN, Suksaranjit P, Bress AP, Witt DM, Han FT, Chelu MG, Silver MA, Biskupiak J, Wilson BD, Morris AK, Kholmovski EG, Marrouche N (2017). Left Atrial Fibrosis and Risk of Cerebrovascular and Cardiovascular Events in Patients With Atrial Fibrillation. J Am Coll Cardiol, 70(11), 1311-1321. (Read full article)
  90. Butler MJ, Tanner RM, Muntner P, Shimbo D, Bress AP, Shallcross AJ, Sims M, Ogedegbe G, Spruill TM (2017). Adherence to antihypertensive medications and associations with blood pressure among African Americans with hypertension in the Jackson Heart Study. J Am Soc Hypertens, 11(9), 581-588.e5. (Read full article)
  91. Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, Berlowitz DR, Conroy MB, Fine L, Oparil S, Morisky DE, Kazis LE, Ruiz-Negron N, Powell J, Tamariz L, Whittle J, Wright JT Jr, Supiano MA, Cheung AK, Weintraub WS, Moran AE (2017). Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 377(8), 745-755. (Read full article)
  92. Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V, SPRINT Research Group (2017). Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care. (Read full article)
  93. Booth JN 3rd, Abdalla M, Tanner RM, Diaz KM, Bromfield SG, Tajeu GS, Correa A, Sims M, Ogedegbe G, Bress AP, Spruill TM, Shimbo D, Muntner P (2017). Cardiovascular Health and Incident Hypertension in Blacks: JHS (The Jackson Heart Study). Hypertension, 70(2), 285-292. (Read full article)
  94. Shallcross AJ, Butler M, Tanner RM, Bress AP, Muntner P, Shimbo D, Ogedegbe G, Sims M, Spruill TM (2017). Psychosocial correlates of apparent treatment-resistant hypertension in the Jackson Heart Study. J Hum Hypertens, 31(7), 486. (Read full article)
  95. Shallcross AJ, Butler M, Tanner RM, Bress AP, Muntner P, Shimbo D, Ogedegbe G, Sims M, Spruill TM (2017). Psychosocial correlates of apparent treatment-resistant hypertension in the Jackson Heart Study. J Hum Hypertens, 31(7), 474-478. (Read full article)
  96. Ravenell J, Shimbo D, Booth JN 3rd, Sarpong DF, Agyemang C, Beatty Moody DL, Abdalla M, Spruill TM, Shallcross AJ, Bress AP, Muntner P, Ogedegbe G (2017). Thresholds for Ambulatory Blood Pressure Among African Americans in the Jackson Heart Study. Circulation, 135(25), 2470-2480. (Read full article)
  97. King JB, Shah RU, Sainski-Nguyen A, Biskupiak J, Munger MA, Bress AP (2017). Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure. Pharmacotherapy, 37(6), 662-672. (Read full article)
  98. Kansal MM, Mansour IN, Ismail S, Bress A, Wu G, Mirza O, Marpadga R, Gheith H, Kim Y, Li Y, Cavallari L, Stamos TD (2017). Left ventricular global longitudinal strain predicts mortality and heart failure admissions in African American patients. Clin Cardiol, 40(5), 314-321. (Read full article)
  99. Bress AP, Kramer H, Khatib R, Beddhu S, Cheung AK, Hess R, Bansal VK, Cao G, Yee J, Moran AE, Durazo-Arvizu R, Muntner P, Cooper RS (2017). Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey). Circulation, 135(17), 1617-1628. (Read full article)
  100. Bress AP, Colantonio LD, Booth JN 3rd, Spruill TM, Ravenell J, Butler M, Shallcross AJ, Seals SR, Reynolds K, Ogedegbe G, Shimbo D, Muntner P (2017). Modifiable Risk Factors Versus Age on Developing High Predicted Cardiovascular Disease Risk in Blacks. J Am Heart Assoc, 6(2). (Read full article)
  101. Mansour IN, Bress AP, Groo V, Ismail S, Wu G, Patel SR, Duarte JD, Kittles RA, Stamos TD, Cavallari LH (2016). Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. J Card Fail, 22(9), 692-9. (Read full article)
  102. Tajeu GS, Kent ST, Kronish IM, Huang L, Krousel-Wood M, Bress AP, Shimbo D, Muntner P (2016). Trends in Antihypertensive Medication Discontinuation and Low Adherence Among Medicare Beneficiaries Initiating Treatment From 2007 to 2012. Hypertension, 68(3), 565-75. (Read full article)
  103. Stone RH, Bress AP, Nutescu EA, Shapiro NL (2016). Upper-Extremity Deep-Vein Thrombosis: A Retrospective Cohort Evaluation of Thrombotic Risk Factors at a University Teaching Hospital Antithrombosis Clinic. Ann Pharmacother, 50(8), 637-44. (Read full article)
  104. Bress AP, Tanner RM, Hess R, Gidding SS, Colantonio LD, Shimbo D, Muntner P (2016). Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups: Age <50 Years, Diabetes Mellitus, or a History of Stroke. J Am Heart Assoc, 5(7). (Read full article)
  105. Bress A, Tanner RM, Hess R, Gidding SS, Colantonio LD, Shimbo D, Muntner P (2016). Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups: Age <50 Years, Diabetes, or a History of Stroke. J Am Soc Hypertens, 10 Suppl 1, e6-e7. (Read full article)
  106. King JB, Shah RU, Bress AP, Nelson RE, Bellows BK (2016). Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail, 4(5), 392-402. (Read full article)
  107. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P (2016). Generalizability of SPRINT Results to the U.S. Adult Population. J Am Coll Cardiol, 67(5), 463-72. (Read full article)
  108. Bress AP, King JB, Brixner D, Kielhorn A, Patel HK, Maya J, Lee VC, Biskupiak J, Munger M (2016). Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center. Pharmacotherapy, 36(2), 174-86. (Read full article)
  109. Brixner D, Biltaji E, Bress A, Unni S, Ye X, Mamiya T, Ashcraft K, Biskupiak J (2016). The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ, 19(3), 213-28. (Read full article)
  110. Biskupiak JE, Biltaji E, Bress A, Unni S, Ye X, Yu B, Mamiya T, Brixner D (2015). Value Assessment for Genetic Testing of Drug Variation In An Elderly Population. Value Health, 18(7), A747. (Read full article)
  111. King JB, Bress AP, Reese AD, Munger MA (2015). Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review. Pharmacotherapy, 35(9), 823-37. (Read full article)
  112. Bress A, Kittles R, Wing C, Hooker SE Jr, King A (2015). Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. Pharmacogenet Genomics, 25(6), 305-12. (Read full article)
  113. Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, Cavallari LH (2015). Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics, 25(2), 73-81. (Read full article)
  114. Sharabiani A, Bress A, Douzali E, Darabi H (2015). Revisiting Warfarin Dosing Using Machine Learning Techniques. Comput Math Methods Med, 2015, 560108. (Read full article)
  115. DiDomenico RJ, Bress AP, Na-Thalang K, Tsao YY, Groo VL, Deyo KL, Patel SR, Bishop JR, Bauman JL (2014). Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure. Pharmacotherapy, 34(11), 1121-31. (Read full article)
  116. McConeghy KW, Bress A, Qato DM, Wing C, Nutescu EA (2014). Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Pharmacotherapy, 34(6), 561-9. (Read full article)
  117. Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, Desai AA, Duarte JD, Gordeuk V, Peace D, Kadkol SS, Dodge C, Saraf S, Garofalo J, Krishnan JA, Garcia JG, Cavallari LH (2013). Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy, 33(11), 1156-64. (Read full article)
  118. Bress A, Han J, Patel SR, Desai AA, Mansour I, Groo V, Progar K, Shah E, Stamos TD, Wing C, Garcia JG, Kittles R, Cavallari LH (2013). Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure. PLoS One, 8(7), e71268. (Read full article)
  119. Kane SP, Bress AP, Tesoro EP (2013). Characterization of unbound phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation. Ann Pharmacother, 47(5), 628-36. (Read full article)
  120. Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH (2012). Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics, 13(16), 1925-35. (Read full article)
  121. Cavallari LH, Jeong H, Bress A (2011). Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med, 4, 123-36. (Read full article)
  122. Bress AP, Filtz MR, Truong HA, Nalder M, Vienet M, Boyle C (2011). An Advanced Pharmacy Practice Experience in Melbourne, Australia: Practical Guidance for Global Experiences. Curr Pharm Teach Learn, 1(3), 53-62.

Review

  1. Todd OM, Knight M, Jacobs JA, Derington CG, Sheppard JP, Bress AP (2024). Pharmacologic Treatment of Hypertension in Older Adults. [Review]. Clin Geriatr Med, 40(4), 629-644. (Read full article)
  2. Bress AP, Anderson TS, Flack JM, Ghazi L, Hall ME, Laffer CL, Still CH, Taler SJ, Zachrison KS, Chang TI, American Heart Association Council on Hypertension Council on Cardiovascular and Stroke Nursing and Council on Clinical Cardiology (2024). The Management of Elevated Blood Pressure in the Acute Care Setting: A Scientific Statement From the American Heart Association. [Review]. Hypertension. (Read full article)
  3. Marcum ZA, Cohen JB, Larson EB, Williamson J, Bress AP (2022). Can Preferentially Prescribing Angiotensin II Receptor Blockers (ARBs) over Angiotensin-Converting Enzyme Inhibitors (ACEIs) Decrease Dementia Risk and Improve Brain Health Equity? [Review]. NAM Perspect, 2022. (Read full article)

Editorial

  1. Cohen JB, Bress AP (2024). Quantifying antihypertensive effects of GLP-1 agonists. Eur Heart J, 45(38), 4135-4137. (Read full article)
  2. Cohen JB, Bress AP (2023). Entering a New Era of Antihypertensive Therapy. Am J Kidney Dis. (Read full article)
  3. Shah RU, Bress AP, Vickers AJ (2022). Do Prediction Models Do More Harm Than Good? Circ Cardiovasc Qual Outcomes, 15(4), e008667. (Read full article)
  4. Bress AP, King JB (2019). Optimizing Medical Therapy in Chronic Worsening HFrEF: A Long Way to Go. J Am Coll Cardiol, 73(8), 945-947. (Read full article)
  5. Bress AP, Irvin MR, Muntner P (2017). Genetics of Blood Pressure: New Insights Into a Complex Trait. Am J Kidney Dis, 69(6), 723-725. (Read full article)

Letter

  1. King JB, Sakhuja S, Derington CG, Kolm P, Herrick JS, Berchie RO, Shen J, Greene T, Tajeu GS, Howard G, Levitan EB, Muntner P, Safford MM, Ying J, Weintraub WS, Moran AE, Bress AP, Bellows BK (2024). Annual Cost of Implementing Intensive Systolic Blood Pressure Goals in the United States. [Letter to the editor]. J Am Heart Assoc, 13(18), e034515. (Read full article)
  2. Parcha V, Pampana A, Bress AP, Irvin MR, Arora G, Arora P (2022). Association of Polygenic Risk Score With Blood Pressure and Adverse Cardiovascular Outcomes in Individuals With Type II Diabetes: Insights From the ACCORD Trial. [Letter to the editor]. Hypertension, 79(5), e100-e102. (Read full article)
  3. Zheutlin AR, Caldwell D, Anstey DE, Conroy MB, Ogedegbe O, Bress AP (2020). Trends in Hypertension Clinical Trials Focused on Interventions Specific for Black Adults: An Analysis of ClinicalTrials.gov. [Letter to the editor]. J Am Heart Assoc, 9(24), e018512. (Read full article)
  4. Cohen JB, Hanff TC, South AM, Sparks MA, Hiremath S, Bress AP, Byrd JB, Chirinos JA (2020). Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19". [Letter to the editor]. Circ Res, 126(12), e140-e141. (Read full article)
  5. Bress AP, Muntner P, Moran AE (2019). Response by Bress et al to Letters Regarding Article, "Potential Cardiovascular Disease Events Prevented With Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline". [Letter to the editor]. Circulation, 139(23), e1023-e1024. (Read full article)

Other

  1. Cohen JB, Marcum ZA, Zhang C, Derington CG, Greene TH, Ghazi L, Herrick JS, King JB, Cheung AK, Bryan N, Supiano MA, Sonnen JA, Weintraub WS, Scharfstein D, Williamson J, Pajewski NM, Bress AP, Systolic Blood Pressure Intervention Trial SPRINT Research Group (2022). Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Netw Open (5(7), pp. e2220680). United States. (Read full article)
  2. Dolui S, Detre JA, Gaussoin SA, Herrick JS, Wang DJJ, Tamura MK, Cho ME, Haley WE, Launer LJ, Punzi HA, Rastogi A, Still CH, Weiner DE, Wright JT Jr, Williamson JD, Wright CB, Bryan RN, Bress AP, Pajewski NM, Nasrallah IM (2023). Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow: Secondary Analysis of the SPRINT MIND Randomized Clinical Trial. JAMA Neurol (79(4), pp. 380-389). United States. (Read full article)
  3. Zheutlin AR, Mondesir FL, Derington CG, King JB, Zhang C, Cohen JB, Berlowitz DR, Anstey DE, Cushman WC, Greene TH, Ogedegbe O, Bress AP (2022). Analysis of Therapeutic Inertia and Race and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open (5(1), pp. e2143001). United States. (Read full article)
  4. Bress AP, Cohen JB, Anstey DE, Conroy MB, Ferdinand KC, Fontil V, Margolis KL, Muntner P, Millar MM, Okuyemi KS, Rakotz MK, Reynolds K, Safford MM, Shimbo D, Stuligross J, Green BB, Mohanty AF (2021). Inequities in Hypertension Control in the United States Exposed and Exacerbated by COVID-19 and the Role of Home Blood Pressure and Virtual Health Care During and After the COVID-19 Pandemic. J Am Heart Assoc (10(11), pp. e020997). England. (Read full article)